February 25, 2022 07:30 AM ESTUpdated 07:51 AM
Pharma
FDA+

Watch out, No­var­tis: Eli Lil­ly, Boehringer In­gel­heim notch broad heart fail­ure OK for Jar­diance

Amber Tong

Eli Lil­ly and Boehringer In­gel­heim just got the green light to go much deep­er in­to the heart fail­ure mar­ket with their SGLT2 in­hibitor Jar­diance. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times